Merck and Co Inc (MRK) - News Archive

European Commission Approves KEYTRUDA as Neoadjuvant and Adjuvant Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma Amidst Evolving Financial Landscape for Merck & Co., Inc.In an important stride for ca...

Transformative Advances in Bladder Cancer Treatment against a Backdrop of Financial Shifts for Merck In the rapidly evolving landscape of pharmaceutical innovations, Merck & Co., known as MSD outside the United States a...

Exploring the FDA Approval of KEYTRUDA QLEX: A New Avenue for Solid Tumor Treatment and Its Implications for Merck & Co., Inc. In a significant advancement in cancer therapy, the U.S. Food and Drug Administration (FDA)...

: Merck & Co., Inc. has received U.S. Food and Drug Administration (FDA) approval for its new subcutaneous formulation of KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph). This innovative therapy aims to im...

AbstractThe recent approvals of KEYTRUDA (pembrolizumab) signify a substantial advancement in the treatment landscape for head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC). Merck s col...

Innovative Advances in Immuno-Oncology: Subcutaneous Pembrolizumab Shows Promising Results in Latest Phase 3 Trial In a groundbreaking step for cancer treatment delivery methods, Merck & Co. also known as MSD outside th...

In a significant advancement for cancer therapy, Merck & Co. Inc. has announced that its anti-PD-1 therapy, KEYTRUDA (pembrolizumab), has received approval from the National Medical Products Administration (NMPA) in Chi...

In a significant development in the biopharmaceutical industry, Merck & Co. known as MSD outside North America, has entered into an exclusive global license agreement with Hansoh Pharma for HS-10535, an investigational...

In recent announcements, AstraZeneca and Merck have unveiled significant advancements in cancer treatment through their respective clinical trials, affirming their commitment to improving survival outcomes for patients...

The American Society of Hematology (ASH) Annual Meeting and Exposition, set to take place in San Diego from December 7-10, 2024, promises to be a pivotal moment for Merck & Co. Inc. (NYSE: MRK). Known as MSD outside the...

In the rapidly evolving realm of oncology therapies, the recent announcement by Merck & Co. Inc. (referred to as Merck) regarding the positive topline results from its pivotal Phase 3 trial (MK-3475A-D77) has elicited s...

Merck Achieves Significant Milestone with Positive EU CHMP Opinion for KEYTRUDA in Combating Malignant Pleural Mesothelioma A Promising Step Forward in Mesothelioma TreatmentRahway, N.J. Merck & Co. Inc. an American mul...

: This article presents an examination of recent pivotal clinical trials highlighting Merck s continued advancements in the field of oncology and ophthalmology. The focus is on KEYTRUDA (pembrolizumab), an anti-PD-1 the...

Merck Advances in Oncology and Ophthalmology: Key Approvals and Clinical Trials Reshape Future TherapiesMerck (NYSE: MRK), recognized as MSD outside of the United States and Canada, continues to make significant strides...

In recent developments surrounding cancer therapies, Merck & Co. Inc. has garnered attention with the announcement of ten-year follow-up data from its pivotal Phase 3 KEYNOTE-006 trial. This clinical study evaluated KEY...

In a significant step forward in the treatment of diabetic macular edema (DME), Merck (NYSE: MRK), known as MSD outside the United States and Canada, and its wholly-owned subsidiary EyeBio have announced the initiation...

Merck Discontinues KEYTRUDA Phase 3 Trial Amidst New Developments In the realm of pharmaceutical endeavors, the esteemed enterprise Merck, known as MSD beyond the borders of the United States and Canada, has furnished t...

The pharmaceutical landscape is a dynamic and competitive arena where strategic acquisitions and collaborations can substantially shape a company’s portfolio. Merck & Co., Inc. (known as MSD outside the United States an...

By: New York, July 30, 2024 — The stock market ended in the red on Tuesday following a series of notable earnings reports that seemed to overshadow the positive close seen on Monday. The focus of tod...

Merck, a leading pharmaceutical company, has completed the acquisition of EyeBio, a promising retinal disease research company. With this acquisition, Merck aims to enhance its late-stage pipeline and enrich its portfol...